2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.10 Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

EP.11A.10 Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study presented investigates the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC) among different age groups, with a focus on chronological and biological age. This research addresses concerns regarding the underrepresentation of older populations in clinical trials and the potential influence of immunosenescence on ICI efficacy.<br /><br />Conducted at a tertiary hospital in Spain, this retrospective study involved 247 patients aged 18 and above, all diagnosed with advanced NSCLC and candidates for first-line ICI treatment. The study stratified patients by chronological age (70 years and older vs. younger than 70) and biological age, as indicated by the number of comorbidities (0-2 vs. 3 or more).<br /><br />Results demonstrated no statistically significant differences in overall survival (OS) based solely on chronological age, with median OS being 18 months for those under 70 and 15 months for those 70 and over. However, when biological age was considered using comorbidity count as a surrogate, a noticeable difference emerged. Patients with fewer comorbidities (0-2) experienced significantly longer median OS (28 months) compared to those with 3 or more comorbidities (13 months), indicating that biological factors might play a more critical role than chronological age in affecting treatment outcomes.<br /><br />The study suggests that while chronological age alone may not impact ICI efficacy, biological age, determined by comorbidities, could be a crucial determinant of prognosis. The findings advocate for personalized treatment approaches and further research into the biological aging process to improve NSCLC treatment strategies. The study acknowledges support from the Carlos III Health Institute and highlights the importance of continued exploration into the specifics of immunosenescence in this context.

Asset Subtitle

Guillermo Suay

Meta Tag

Speaker Guillermo Suay

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immune checkpoint inhibitors

non-small cell lung cancer

chronological age

biological age

immunosenescence

comorbidities

overall survival

personalized treatment

NSCLC treatment

Carlos III Health Institute